Comparison of IHC, FISH and RT-PCR Methods for Detection of ALK Rearrangements in 312 Non-Small Cell Lung Cancer Patients in Taiwan

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wu, Yi Cheng ^a   Chang, Il Chi ^b   Wang, Chi Liang ^a   Chen, Tai Di ^c   Chen, Ya Ting ^b   Liu, Hui Ping ^a   Chu, Yen ^a   Chiu, Yu Ting ^b   Wu, Tzu Hua ^b   Chou, Li Hui ^b   Chen, Yi Rong ^b   Huang, Shiu Feng ^b,c,d,e  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI TZU CHI HOSPITAL   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CAUCASIAN; CHINESE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; JAPANESE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PREDICTIVE VALUE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING HABIT; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KINESIN; LUNG NEOPLASMS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TAIWAN; YOUNG ADULT;

EID: 84881339295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070839     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. doi:10.3322/CA.2007.0010. PubMed: 18287387.
3. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128. doi:10.1016/S1470-2045(09)70364-X. PubMed: 20022809.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. doi:10.1056/NEJMoa0810699. PubMed: 19692680.
5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388. doi:10.1056/NEJMoa0909530. PubMed: 20573926.
6. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, et al. (2011) A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 6: 1379-1391. doi:10.1097/JTO.0b013e318220cb8e. PubMed: 21709590.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. doi:10.1056/NEJMoa040938. PubMed: 15118073.
8. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566. doi:10.1038/nature05945. PubMed: 17625570.
9. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G, (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8: 11-23. doi:10.1038/nrc2291. PubMed: 18097461.
10. Palmer RH, Vernersson E, Grabbe C, Hallberg B, (2009) Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420: 345-361. doi:10.1042/BJ20090387. PubMed: 19459784.
11. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J, (1998) Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18: 6951-6961. PubMed: 9819383.
12. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, et al. (2003) NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101: 1919-1927. doi:10.1182/blood-2002-05-1343. PubMed: 12424201.
13. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, et al. (2011) Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 47: R11-R23. doi:10.1530/JME-11-0004. PubMed: 21502284.
14. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, et al. (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68: 4971-4976. doi:10.1158/0008-5472.CAN-07-6158. PubMed: 18593892.
15. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, et al. (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149. doi:10.1158/1078-0432.CCR-08-3248. PubMed: 19383809.
16. Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, et al. (2011) A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 117: 2709-2718. doi:10.1002/cncr.25843. PubMed: 21656749.
17. Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, et al. (2012) KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLOS ONE 7: e31323. doi:10.1371/journal.pone.0031323. PubMed: 22347464.
18. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, et al. (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61: 163-169. doi:10.1016/j.lungcan.2007.12.013. PubMed: 18242762.
19. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, et al. (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13-17. doi:10.1097/JTO.0b013e31815e8b60. PubMed: 18166835.
20. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, et al. (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14: 6618-6624. doi:10.1158/1078-0432.CCR-08-1018. PubMed: 18927303.
21. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14: 4275-4283. doi:10.1158/1078-0432.CCR-08-0168. PubMed: 18594010.
22. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515. doi:10.1038/modpathol.2009.2. PubMed: 19234440.
23. Lin E, Li L, Guan Y, Soriano R, Rivers CS, et al. (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7: 1466-1476. doi:10.1158/1541-7786.MCR-08-0522. PubMed: 19737969.
24. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733. doi:10.1002/cncr.24181. PubMed: 19170230.
25. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661-670. doi:10.2353/ajpath.2009.080755. PubMed: 19147828.
26. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, et al. (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889-897. doi:10.1245/s10434-009-0808-7. PubMed: 20183914.
27. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, et al. (2010) Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 9: 188. doi:10.1186/1476-4598-9-188. PubMed: 20624322.
28. Sanders HR, Li HR, Bruey JM, Scheerle JA, Meloni-Ehrig AM, et al. (2011) Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 204: 45-52. doi:10.1016/j.cancergencyto.2010.08.024. PubMed: 21356191.
29. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703. doi:10.1056/NEJMoa1006448. PubMed: 20979469.
30. Camidge DR, Bang Y, Kwak EL, Shaw AT, Lafrate AJ, et al. (2011) Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 29 (suppl): abstr 2501.
31. Crinò L, Kim D, Riely GJ, Janne PA, Blackhall FH, et al. (2011) Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE. J Clin Oncol 1005 (29 suppl):: abstr 7514.
32. Ou SH, (2011) Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drugs Devel Ther 5: 471-485. PubMed: 22162641.
33. Lamant L, Meggetto F, al Saati T, Brugières L, de Paillerets BB, et al. (1996) High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 87: 284-291. PubMed: 8547653.
34. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, et al. (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89: 1394-1404. PubMed: 9028963.
35. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, Tsujimoto M, (2010) Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 63: 1066-1070. doi:10.1136/jcp.2010.081166. PubMed: 20935334.
36. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6: 466-472. doi:10.1097/JTO.0b013e31820b82e8. PubMed: 21258247.
37. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, et al. (2011) Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6: 459-465. doi:10.1097/JTO.0b013e318209edb9. PubMed: 21278610.
38. Park HS, Lee JK, Kim DW, Kulig K, Kim TM, et al. (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77: 288-292. doi:10.1016/j.lungcan.2012.03.004. PubMed: 22465695.
39. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, et al. (2009) Unique Clinicopathologic Features Characterize ALK-rearranged Lung Adenocarcinoma in the Western Population. Clin Cancer Res 15: 5216-5223. doi:10.1158/1078-0432.CCR-09-0802. PubMed: 19671850.
40. Hofman P, Ilie M, Hofman V, Roux S, Valent A, et al. (2012) Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 23: 1738-1743. doi:10.1093/annonc/mdr535. PubMed: 22100693.
41. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ, (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 136: 796-803. doi:10.5858/arpa.2011-0321-OA. PubMed: 22742552.
42. Chen TD, Chang IC, Liu HP, Wu YC, Wang CL, et al. (2012) Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study. Chang Gung Med J 35: 309-317. PubMed: 22913857.
43. Li Y, Li Y, Yang T, Wei S, Wang J, et al. (2013) Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLOS ONE 8: e52093. doi:10.1371/journal.pone.0052093. PubMed: 23341890.
44. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, et al. (2012) Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 18: 4682-4690. doi:10.1158/1078-0432.CCR-11-3260. PubMed: 22912387.
45. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, et al. (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71: 6051-6060. doi:10.1158/0008-5472.CAN-11-1340. PubMed: 21791641.
46. Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, et al. (2012) EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7: 98-104. doi:10.1097/JTO.0b013e3182370e30. PubMed: 22124476.
47. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203. doi:10.1158/1078-0432.CCR-04-1245. PubMed: 15623594.
48. Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, et al. (2008) Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 113 (supp).:: 3199-3208. doi:10.1002/cncr.23925. PubMed: 18932251.